Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss...
Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss...
Altamira Therapeutics 提供 RNA 交付平台的最新業務信息；宣佈改善 RNA 納米顆粒穩定性，探索 AM-125 在眩暈和中樞神經系統適應症方面的合作機會，並切換瑞士的財務報告...
Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss Francs To US Dollars
Altamira Therapeutics 提供 RNA 交付平台的最新業務信息；宣佈改善 RNA 納米顆粒穩定性，探索 AM-125 在眩暈和中樞神經系統適應症方面的合作機會，並將財務報告從瑞士法郎改爲美元
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。